Antimicrobials: A lysin to kill
Being in the right place at the right time is a recipe for success for an antibacterial compound. Streptococcus pyogenes (often simply called Spy) is a bacterium that is responsible for a range of human infections, from the common “strep throat” to necrotizing fasciitis, the life-threatening condition also known as “flesh-eating disease” (Ralph and Carapetis, 2013). Spy infections can often return after treatment because the bacteria can invade human cells, which protect them from both our immune system and antibiotics (Osterlund et al., 1997). Now, in eLife, Daniel Nelson from the University of Maryland and co-workers – including Yang Shen (Maryland) and Marilia Barros (Carnegie Mellon University) as joint first authors – report the unexpected ability of an antimicrobial enzyme called PlyC to find and kill Spy that is hiding inside human cells (Shen et al., 2016).
PlyC is produced by a bacteriophage, a virus that infects bacterial cells. Like all viruses, bacteriophages commandeer their host’s replication machinery to produce copies of themselves. Some bacteriophages also carry genes for enzymes called endolysins or phage lysins that allow them to escape from the bacteria they have invaded by degrading the mesh-like cell wall that protects each bacterial cell.
The medical potential of bacteriophages and phage lysins was recognized shortly after they were discovered over a century ago. In fact, bacteriophage treatment was used for a range of illnesses in the early 20th Century (Chanishvili, 2012), but it was quickly overshadowed by small-molecule antibiotics from the 1940s onwards. The widespread use of antibiotics in medicine and agriculture has, unfortunately and inevitably, led to the spread of antibiotic-resistant bacteria and a possible end to the “Antibiotic Era” (Harrison and Svec, 1998; Boucher et al., 2009). Also, more people are now aware that using broad-spectrum antimicrobial drugs can alter the microbial community in the gut, which in turn can impact on human health (Cotter et al., 2012).
Phage lysins possess a number of good antimicrobial traits. They are potent, fast-acting, specific to a narrow range of bacteria and relatively harmless to other types of cells. They can also kill bacteria that are dormant or not actively growing (Fischetti, 2010), and have been used to cure short-term Spy infections in mice (Gilmer et al., 2013). However, most had assumed that these enzymes were incapable of entering into host cells, and unlikely to be useful for treating chronic Spy infections in humans.
Shen, Barros and colleagues, who are based at various centers across the United States, attempted to overcome this assumed limitation by fusing phage lysins with fragments of proteins that help transport other molecules through cell membranes. Serendipitously, they discovered that PlyC is intrinsically active against intracellular Spy. PlyC is the only known phage lysin that is composed of two subunits. One of these subunits (PlyCA) is enzymatically active and degrades the bacterial cell wall. The other subunit (PlyCB) binds to the Spy cell surface and, as discovered by Shen, Barros et al., is needed to get the enzyme inside a human epithelial cell (Figure 1).
The PlyCB subunit was known to have a positively charged surface (McGowan et al., 2012), and so Shen, Barros et al. hypothesized that it interacts with negatively charged components of the cell membrane. Indeed, they then went on to discover that PlyCB binds to a negatively charged molecule called phosphatidylserine that is common in eukaryotic cell membranes. Their results also suggested that PlyCB can only penetrate membranes that contain at least 30% phosphatidylserine.
Regions of the cell membrane called lipid rafts have high levels of phosphatidylserine, and are involved in the uptake of numerous molecules from the cell’s exterior via a process called endocytosis (Pike, 2009). This suggested that PlyC might enter cells via an endocytic mechanism, and Shen, Barros et al. provided further support for this idea by showing that PlyCB co-localizes with another protein that binds to lipid rafts. Based on these data and some molecular modeling, they proposed that PlyCB binds to phosphatidylserine, causes the membrane to fold around it, and ultimately enters the cell via endocytosis (Figure 1).
These new findings demonstrate the potential of phage lysins, and possibly bacteriophage-based therapy, to treat challenging bacterial infections. Specifically, they also highlight the potential of PlyC to reduce or even prevent infection with Spy, which remains a major health concern in low- to middle-income countries and disproportionately targets children (Ralph and Carapetis, 2013). Further work is needed to confirm if PlyC enters cells via lipid raft-mediated endocytosis, and to determine how PlyC ultimately meets the intracellular Spy in order to kill it. However, insights provided by Shen, Barros et al. open up the possibility of engineering new endolysins based on PlyCB to target other disease-causing microbes that evade the immune system by hiding in an infected person’s cells.
References
-
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaClinical Infectious Diseases 48:1–12.https://doi.org/10.1086/595011
-
The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencingDiscovery Medicine 13:193–199.
-
Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogensInternational Journal of Medical Microbiology 300:357–362.https://doi.org/10.1016/j.ijmm.2010.04.002
-
Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy 57:2743–2750.https://doi.org/10.1128/AAC.02526-12
-
The beginning of the end of the antibiotic era? Part I. The problem: Abuse of the "miracle drugs"Quintessence International 29:151–162.
-
X-ray crystal structure of the streptococcal specific phage lysin PlyCProceedings of the National Academy of Sciences of the United States of America 109:12752–12757.https://doi.org/10.1073/pnas.1208424109
-
The challenge of lipid raftsJournal of Lipid Research 50 Suppl:S323–328.https://doi.org/10.1194/jlr.R800040-JLR200
-
Group a streptococcal diseases and their global burdenCurrent Topics in Microbiology and Immunology 368:1–27.https://doi.org/10.1007/82_2012_280
Article and author information
Author details
Publication history
- Version of Record published: April 27, 2016 (version 1)
Copyright
© 2016, Gaca et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,989
- views
-
- 254
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Evolutionary Biology
Stramenopiles form a clade of diverse eukaryotic organisms, including multicellular algae, the fish and plant pathogenic oomycetes, such as the potato blight Phytophthora, and the human intestinal protozoan Blastocystis. In most eukaryotes, glycolysis is a strictly cytosolic metabolic pathway that converts glucose to pyruvate, resulting in the production of NADH and ATP (Adenosine triphosphate). In contrast, stramenopiles have a branched glycolysis in which the enzymes of the pay-off phase are located in both the cytosol and the mitochondrial matrix. Here, we identify a mitochondrial carrier in Blastocystis that can transport glycolytic intermediates, such as dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, across the mitochondrial inner membrane, linking the cytosolic and mitochondrial branches of glycolysis. Comparative analyses with the phylogenetically related human mitochondrial oxoglutarate carrier (SLC25A11) and dicarboxylate carrier (SLC25A10) show that the glycolytic intermediate carrier has lost its ability to transport the canonical substrates malate and oxoglutarate. Blastocystis lacks several key components of oxidative phosphorylation required for the generation of mitochondrial ATP, such as complexes III and IV, ATP synthase, and ADP/ATP carriers. The presence of the glycolytic pay-off phase in the mitochondrial matrix generates ATP, which powers energy-requiring processes, such as macromolecular synthesis, as well as NADH, used by mitochondrial complex I to generate a proton motive force to drive the import of proteins and molecules. Given its unique substrate specificity and central role in carbon and energy metabolism, the carrier for glycolytic intermediates identified here represents a specific drug and pesticide target against stramenopile pathogens, which are of great economic importance.
-
- Biochemistry and Chemical Biology
Protein phosphorylation is one of the major molecular mechanisms regulating protein activity and function throughout the cell. Pannexin 1 (PANX1) is a large-pore channel permeable to ATP and other cellular metabolites. Its tyrosine phosphorylation and subsequent activation have been found to play critical roles in diverse cellular conditions, including neuronal cell death, acute inflammation, and smooth muscle contraction. Specifically, the non-receptor kinase Src has been reported to phosphorylate Tyr198 and Tyr308 of mouse PANX1 (equivalent to Tyr199 and Tyr309 of human PANX1), resulting in channel opening and ATP release. Although the Src-dependent PANX1 activation mechanism has been widely discussed in the literature, independent validation of the tyrosine phosphorylation of PANX1 has been lacking. Here, we show that commercially available antibodies against the two phosphorylation sites mentioned above—which were used to identify endogenous PANX1 phosphorylation at these two sites—are nonspecific and should not be used to interpret results related to PANX1 phosphorylation. We further provide evidence that neither tyrosine residue is a major phosphorylation site for Src kinase in heterologous expression systems. We call on the field to re-examine the existing paradigm of tyrosine phosphorylation-dependent activation of the PANX1 channel.